# Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)

> **NCT01380938** · PHASE3 · COMPLETED · sponsor: **Casa Sollievo della Sofferenza IRCCS** · enrollment: 1150 (actual)

## Conditions studied

- Chronic Hepatitis

## Interventions

- **DRUG:** Peginterferon alpha-2a + Ribavirin

## Key facts

- **NCT ID:** NCT01380938
- **Lead sponsor:** Casa Sollievo della Sofferenza IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2019-11-30
- **Final completion:** 2019-11-30
- **Target enrollment:** 1150 (ACTUAL)
- **Last updated:** 2022-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380938, "Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT01380938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*